Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Here's What Happened

Key Points

• Genmab A/S shares opened at $232.30 after closing at $216.31, indicating a significant gap up in price.
• The company's recent earnings report showed an earnings per share (EPS) of $5.42, which exceeded analysts' expectations of $3.99.
• Genmab A/S has a market cap of $15.35 billion and a net margin of 37.53% from its latest quarter's revenue of $925 million.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $216.31, but opened at $232.30. Genmab A/S shares last traded at $232.30, with a volume of 17 shares traded.

Genmab A/S Stock Up 3.7%

The firm's 50-day moving average is $216.74 and its 200-day moving average is $208.02. The company has a market capitalization of $15.92 billion, a PE ratio of 12.10 and a beta of 0.93.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million during the quarter, compared to analyst estimates of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.